

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
28 October 2004 (28.10.2004)

PCT

(10) International Publication Number  
**WO 2004/091723 A1**

(51) International Patent Classification<sup>7</sup>: A61P 7/02, 25/28

(21) International Application Number:

PCT/IL2004/000327

(22) International Filing Date: 15 April 2004 (15.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/462,701 15 April 2003 (15.04.2003) US

(71) Applicant (for all designated States except US): OP-  
PERBAS HOLDING B.V. [NL/NL]; Hockenrode 6 - 8,  
NL-1102 BR Amsterdam Zuidoost (NL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BARU, Moshe  
[IL/IL]; Hahadarim Pinat Tarpat Street, 37000 Pardes  
Hana (IL). CARMEL-GOREN, Lea [IL/IL]; 12 Men-  
achem Street, IL-52324 Ramat Gan (IL).

(74) Agent: REINHOLD COHN AND PARTNERS; P.O.B.  
4060, 61040 Tel Aviv (IL).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, CZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

A1

WO 2004/091723

(54) Title: PHARMACEUTICAL COMPOSITION COMPRISING PROTEINS AND/OR POLYPEPTIDES AND COLLOIDAL PARTICLES

(57) Abstract: A pharmaceutical composition for parenteral administration comprising a therapeutically effective amount of a protein or polypeptide and colloidal particles. The particles comprise approximately 1-20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer. The protein or polypeptide is selected from the group consisting of (a) proteins or polypeptides capable of externally binding said colloidal particles; (b) proteins or polypeptides capable of binding polymers of the polyalkylether, polylactic and polyglycolic acid families; and (c) proteins or polypeptides that include a consensus sequence of S/T-X/I/V-I/V/Q/S-S/T-X-X-E, where X may be any amino acid, and S, T, I, V, E and Q have their standard meanings. The protein or polypeptide is not Factor VIII (FVIII) and is not encapsulated in the colloidal particles.

*W/ PCT*  
JC20 Rec'd PCT/PTO 14 OCT 2009

## PHARMACEUTICAL COMPOSITION COMPRISING PROTEINS AND/OR POLYPEPTIDES AND COLLOIDAL PARTICLES

### FIELD OF THE INVENTION

The present invention relates to a pharmaceutical formulation for the increased half-life, efficacy and stability of various proteins and polypeptides.

### BACKGROUND OF THE INVENTION

5 Hemophilia A is one of the most frequently occurring inherited coagulation disorders. Patients with hemophilia A are prone to frequent hemorrhages as a result of one or more misfunctions of the coagulation system. One of the causes of hemophilia is a shortage of Factor VIII (FVIII) in the blood. This problem can be treated with Factor VIII concentrates. However, in about 15% of the patients the 10 occurrence results of Factor VIII neutralizing antibodies, so-called inhibitors, whereby a therapy with Factor VIII concentrates is hardly possible.

Two basic approaches have been described in the literature to protect FVIII from inactivation by inhibitors.

WO/80/01456 to Hemker discloses a pharmaceutical composition suitable 15 for oral administration comprising FVIII incorporated within liposomes of 0.5-1.0 microns formed from phospholipids. The phospholipids have a net charge, and the FVIII is incorporated between the layers of the liposome. It is claimed that FVIII levels in the plasma remained above about 5% of the normal value for a period of 50 hours.

20 US 4,348,384 to Horikoshi states that a composition as described in Hemker was prepared, but did not give satisfactory results. Therefore, Horikoshi incorporates a protease inhibitor into the liposome together with FVIII, in order to

- 2 -

protect it from proteolysis. 3% of the normal plasma levels of FVIII were obtained over a period of 6 hours.

US 5,013,556 to Woodle discloses a liposome composition for use in delivering various drugs via the bloodstream. The liposome contains between 1-20 mole percent of an amphipathic lipid derivatized with a polyalkylether. Here also, the drug compound is entrapped within the liposome. These liposome compositions are available commercially under the name of Stealth® vesicles (SUV's, small unilamellar vesicles comprised of phospholipid and polyethylene glycol (PEG) covalently bound to phospholipid).

A further problem with this approach is that liposomes having a large diameter have a short half-life. Therefore, the liposomes must be downsized under high pressure, which can affect protein activities as in coagulation factors V and VIII.

In a second approach, Barrowcliffe, T.W., *et al.* (1983) *J. Lab. Clin. Med.* 101:34-43 teaches that mixing FVIII with phospholipid extracted from human and/or animal brain imparts significant protection to the FVIII *in vitro*. In this approach, the phospholipid is bound to the FVIII rather than encapsulating it. Kemball-Cook, G. and Barrowcliffe, T.W. (1992) *Thromb. Res.* 67:57-71, teaches that a negatively-charged phospholipid surface is necessary for FVIII binding. Negatively charged phosphatidyl serine and phosphatidic acid were found to be highly active in binding to FVIII, while phosphatidyl choline was inactive. However, negatively-charged phospholipids are toxic, and those derived from brain tissue may carry pathogenic agents.

EP 689,428 discloses a liposome composition comprising liposomes having an outer surface layer of hydrophilic polymer chains. A polypeptide or polysaccharide effector molecule is covalently attached to the distal ends of the polymer chains by activation of the lipid anchor prior to effector coupling.

- 3 -

## SUMMARY OF THE INVENTION

It is an object of the present invention to provide a pharmaceutical composition comprising a protein or polypeptide for therapeutic treatment.

It is a further object of the invention to provide a protein or polypeptide in a form having an extended half-life in the bloodstream.

It is a still further object of the invention to provide a method for treating patients suffering from blood coagulation disorders, particularly hemophilia.

In one aspect of the invention, there is provided a pharmaceutical composition for parenteral administration comprising a therapeutically effective amount of a protein or polypeptide and colloidal particles, said particles comprising approximately 1-20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer, wherein said protein or polypeptide is selected from the group consisting of: (a) proteins or polypeptides capable of externally binding said colloidal particles; (b) proteins or polypeptides capable of binding polymers of the polyalkylether, polylactic and polyglycolic acid families; and (c) proteins or polypeptides that include a consensus sequence of S/T-X-L/I/V-I/V/Q/S-S/T-X-X-E, where X may be any amino acid, and S, T, L, I, V, E and Q have their standard meanings. The protein or polypeptide is not encapsulated in said colloidal particles.

In a preferred embodiment, the colloidal particles are substantially neutral and the polymer carries substantially no net charge. In the present specification, the terms "*substantially neutral*" and "*substantially no net charge*" mean neither positively nor negatively charged. However, a very low measured charge within experimental error of zero is included within the meaning of the above terms.

The present invention is based on the surprising and unexpected finding that liposomes containing amphipathic lipids derivatized with a bio-compatible hydrophilic polymer can be used to bind proteins or polypeptides, enhance their pharmacokinetic parameters (half-life and area under the curve) and protect them from inhibitors in the bloodstream. This provides a significant advantage over the prior art compositions, since the amphipathic lipids used are synthetic and non-

- 4 -

toxic, and can therefore be used *in vivo* for therapeutic treatment. Furthermore, the liposome does not encapsulate the proteins or polypeptides so that smaller sized liposomes can be used which have a longer half-life *in vivo*, since they are not removed by the reticuloendothelial system (RES) and the activity of the formulated 5 proteins or polypeptides is not impaired (full activity found *in vitro* and immediately after injection *in vivo*). As will be described below in greater detail, the proteins or polypeptides interact non-covalently with the polymer chains on the external surface of the liposomes, and no chemical reaction is carried out to activate the polymer chains, unlike the composition disclosed in EP 689,428.

10 The term "*proteins or polypeptides capable of externally binding said colloidal particles*" includes proteins such as coagulation factor VIIa (FVIIa), factor V (FV), factor IX (FIX) and factor X (FX), Granulocyte colony-stimulating factor (G-CSF), Granulocyte macrophage colony-stimulating factor (GM-CSF), Interferon  $\gamma$  and Glucagon-*Like* Peptide 1 (GLP-1), Interferon- $\gamma$  and Glucagon-*Like* 15 Peptide 1 (GLP-1) and a copolymer (Copaxone, Teva, Israel) composed of repeats of 4 amino acids (L-ala, L-glu, L-lys and L-tyr). The identity of these proteins may be ascertained empirically as is known by the skilled man of the art.

The pharmaceutical composition of the invention may be used to treat various diseases, as is known to the skilled man of the art. For example, a 20 composition comprising Copaxone may be used to protect central nervous system (CNS) cells from glutamate toxicity and to treat injury or disease caused or exacerbated by glutamate toxicity. The composition may also be used to treat multiple sclerosis, diabetic neuropathy, senile dementia, Alzheimer's disease, Parkinson's Disease, facial nerve (Bell's) palsy, glaucoma, Huntington's chorea, 25 amyotrophic lateral sclerosis, status epilepticus, non-arteritic optic neuropathy, or vitamin deficiency, as described in US Patent Application No. 20020037848.

The term "*proteins or polypeptides capable of binding polymers of the polyalkylether, polylactic and polyglycolic acid families*" includes proteins and polypeptides which bind to polymers of the polyalkylether, polylactic and 30 polyglycolic acid families or derivatives thereof by any non-covalent mechanism,

- 5 -

such as ionic interactions, hydrophobic interactions, hydrogen bonds and Van der Waals attractions (Arakawa, T. and Timasheff, S.N. (1985) Biochemistry 24:6756-6762; Lee, J.C. and Lee, L.L.Y. (1981) *J. Biol. Chem.* 226:625-631). A preferred example of such a polymer is polyethylene glycol (PEG).

5        The term "*therapeutically effective amount*" is to be understood as referring to an amount of protein or polypeptide which results in a level of the protein or polypeptide in the bloodstream having a desired therapeutic effect. Such an amount can be experimentally determined by administering compositions comprising different amounts of the protein or polypeptide and measuring the level in the blood  
10 at various times after administration.

The amphipathic lipid used to prepare the colloidal particles may be obtained from either natural or synthetic sources. Most preferred lipids include phospholipids such as phosphatidylcholine and phosphatidylethanolamine, and carbamate-linked uncharged lipopolymers such as aminopropanediol distearoyl  
15 (DS). The purpose of the biocompatible hydrophilic polymer is to sterically stabilize the SUVs, thus preventing fusion of the vesicles *in vitro*, and allowing the vesicles to escape adsorption by the RES *in vivo*. The polymer will preferably have a molecular weight of between about 500 to about 5000 daltons, most preferably approximately 2000 daltons.

20        The colloidal particles will preferably have a mean particle diameter of between about 0.03 to about 0.4 microns, most preferably about 0.1 microns. This is to increase their circulation time *in vivo* and prevent their adsorption by the RES. The amphipathic lipid comprises approximately 0.5 to about 20 mole % of the particles, preferably approximately 1-6%, most preferably 3%.

25        A variety of known coupling reactions may be used for preparing vesicle forming lipids derivatized with hydrophilic polymers. For example, a polymer (such as PEG) may be derivatized to a lipid such as phosphatidylethanolamine (PE) through a cyanuric chloride group. Alternatively, a capped PEG may be activated with a carbonyl diimidazole coupling reagent, to form an activated imidazole  
30 compound. A carbamate-linked compound may be prepared by reacting the

- 6 -

terminal hydroxyl of MPEG (methoxyPEG) with p-nitrophenyl chloroformate to yield a p-nitrophenyl carbonate. This product is then reacted with 1-amino-2,3-propanediol to yield the intermediate carbamate. The hydroxyl groups of the diol are acylated to yield the final product. A similar synthesis, using glycerol in place of 5 1-amino-2,3-propanediol, can be used to produce a carbonate-linked product, as described in WO 01/05873. Other reactions are well known and are described, e.g. in the aforementioned U.S. 5,013,556, whose contents are incorporated herein by reference.

The composition of the invention may be administered by injection, 10 preferably iv, sc or im. The prior art compositions were intended for oral use only, due to side effects caused during injection by the liposome composition. The composition of the invention, on the other hand, is not toxic by injection, apparently due to the small size and lack of toxic phospholipids. Toxicology studies of PEGylated liposomes and FVIII in rats have been carried out - no toxicity was 15 found at doses of 500 units/kg. Amounts of up to 0.5gm/Kg body weight of colloidal particles according to the invention have been injected without detectable toxic symptoms. Although the free form of the proteins and polypeptides used in the invention have a short half-life in the vascular system, administering them in the composition of the invention is expected to increase their half-life by at least 1.5 20 times. The composition of the invention is expected to be effective in "on demand" and prophylactic treatment of patients.

In another aspect of the invention, it has been found that there is a consensus sequence of 8 amino acids located within the proteins that binds the liposomes of the invention but is absent in proteins that do not bind the liposomes. This 25 consensus sequence is S/T-X-L/I/V-I/V/Q/S-S/T-X-X-E, where X may be any amino acid, and S, T, L, I, V, E and Q have their standard meanings.

In another aspect of the invention, it has been found that injection of PEGylated liposomes separately from the injection of the protein increases the protein half-life and long-term efficacy.

- 7 -

In a further aspect of the invention, cholesterol is supplemented to the pharmaceutical composition.

#### BRIEF DESCRIPTION OF THE DRAWINGS

In order to understand the invention and to see how it may be carried out in practice, a preferred embodiment will now be described, by way of non-limiting example only, with reference to the accompanying drawings, in which:

**Fig. 1** illustrates a real time interaction of PEGylated liposomes to immobilized FVIII. *a*, PEGylated liposomes , but not control POPC liposomes (PC) and POPC:DSPE liposomes (PC:PE), bind to immobilized rFVIII. *b*, PEGylated liposomes bind to immobilized rFVIII (FVIII) but not to immobilized HSA . *c*, PEGylated liposomes bind to immobilized rFVIII in the absence or presence (Inhibitors) of a diluted (x100) serum of a hemophilia A patient that developed anti FVIII antibodies (titer of 20 Bethesda units/ml). Response is indicated in Resonance Units (RU). Response in *a-c* is corrected for nonspecific binding to HSA coated channel, which was less than 5% Real time interaction of PEGylated liposomes to immobilized FVIII coated channels.

**Fig. 2.** Real time interaction of PEGylated liposomes to immobilized FIX. *a*, PEGylated liposomes bind to immobilized FIX but not to immobilized HSA . *b*, PEGylated liposomes , but not control POPC liposomes , bind to immobilized FIX. Response is indicated in Resonance Units (RU). Response is corrected for nonspecific binding to HSA coated channel, which was less than 5% Real time interaction of PEGylated liposomes to immobilized FIX elative to the binding to FIX coated channels.

**Fig. 3.** Real time interaction of PEGylated liposomes to immobilized G-CSF. *a*, PEGylated liposomes bind to immobilized G-CSF but not to immobilized HSA . *b*, PEGylated liposomes , but not control POPC liposomes , bind to immobilized G-CSF. Response is indicated in Resonance Units (RU). Response is corrected for nonspecific binding to HSA coated channel, which was less than 5%

- 8 -

Real time interaction of PEGylated liposomes to immobilized G-CSF elative to the binding to G-CSF coated channels.

Fig. 4. Real time interaction of PEGylated liposomes to immobilized GM-CSF. a, PEGylated liposomes bind to immobilized GM-CSF but not to immobilized HSA . b, PEGylated liposomes , but not control POPC liposomes , bind to immobilized GM-CSF. Response is indicated in Resonance Units (RU). Response is corrected for nonspecific binding to HSA coated channel, which was less than 5% Real time interaction of PEGylated liposomes to immobilized GM-CSF elative to the binding to G-CSF coated channels.

Fig. 5. Real time interaction of PEGylated liposomes to immobilized Interferon  $\gamma$ . a, PEGylated liposomes bind to immobilized INF- $\gamma$  but not to immobilized HSA . b, PEGylated liposomes , but not control POPC liposomes , bind to immobilized INF- $\gamma$ . Response is indicated in Resonance Units (RU). Response is corrected for nonspecific binding to HSA coated channel, which was less than 5% Real time interaction of PEGylated liposomes to immobilized INF- $\gamma$  elative to the binding to INF- $\gamma$  coated channels.

Fig. 6. Real time interaction of PEGylated liposomes to immobilized GLP-1. a, PEGylated liposomes bind to immobilized GLP-1 but not to immobilized HSA . b, PEGylated liposomes , but not control POPC liposomes , bind to immobilized GLP-1. Response is indicated in Resonance Units (RU). Response is corrected for nonspecific binding to HSA coated channel, which was less than 5% Real time interaction of PEGylated liposomes to immobilized GLP-1 elative to the binding to GLP-1 coated channels.

Fig. 7. PEGylated liposomes bind to immobilized FIX in the absence or presence Antibodies) of a diluted (x10) rabbit polyclonal anti human FIX antibodies (Sigma).

Fig 8. Consensus sequence and FVIII binding sites for PEGylated liposomes. a, Consensus sequence for binding PEGylated liposomes in various proteins. Conserved amino acids are depicted in red whereas unconserved amino acids are depicted in blue. b, Human FVIII domain structure. Discrete domain

- 9 -

structure of human FVIII as deduced from its primary structure. Liposome binding sites are represented as black squares. Red arrows indicated with T represent thrombin activation sites. *c*, Binding of PEGylated liposomes or POPC liposomes (PC) to a peptide derived from FVIII sequence (1783-1796 amino acids) 5 immobilized at a CM5 sensor chip. Response is indicated in Resonance Units (RU).

**Fig. 9.** Real time interaction of PEGylated liposomes to immobilized Copaxone. *a*, PEGylated liposomes bind to immobilized Copaxone but not to immobilized HSA. *b*, PEGylated liposomes, but not control POPC liposomes, bind to immobilized Copaxone. Response is indicated in Resonance Units (RU). 10 Response is corrected for nonspecific binding to HSA coated channel, which was less than 5% Real time interaction of PEGylated liposomes to immobilized Copaxone relative to the binding to Copaxone coated channels.

**Fig. 10.** Survival of hemophilic mice following tail cuts. Kaplan-Meierb plots are shown for hemophilic mice injected with FVIII (Kogenate-FS, Bayer) or 15 FVIII and PEGylated liposomes (injected one hour later). T test statistical analysis indicates statistically significant differences between the groups ( $P<0.05$ ).

**Fig. 11.** Real time interaction of PEGylated liposomes composed of POPC:DSPE-PEG 2000 (lipids from Genzyme Pharmaceuticals, Liestal, Switzerland) with 97:3 mole ratio, respectively, and PEGylated liposomes 20 composed of POPC:DS-c-PEG2000 (lipids from Genzyme Pharmaceuticals, Liestal, Switzerland) with 97:3 mole ratio, respectively, to immobilized FVIII.

## DETAILED DESCRIPTION OF THE INVENTION

### 1. Examples 1-8

#### 1.1 Material & Methods

25 Liposome preparation. Liposomes composed of palmitoyl-oleoyl phosphatidyl-choline (POPC) and distearoyl phosphatidyl-ethanolamine methyl polyethylene glycol 2000 (DSPE-PEG 2000) (Genzyme Pharmaceuticals, Liesatal, Switzerland) (97:3 molar ratio, respectively), POPC and distearoyl phosphatidyl-ethanolamine (DSPE) (Aventi Polar Lipids, Alabaster AL, USA) (97:3 molar ratio,

- 10 -

respectively) were prepared as follows: lipids were dissolved to 10% w/v in tert-butanol (Reidel-de Haen, Seelze, Germany), frozen and the solution was lyophilized. The resulting dry lipid powder was re-suspended to 2-13% (w/v) in a 50 mM sodium citrate buffer, pH 7.0 to form liposomes. The liposomes were 5 filtered using LiposoFast<sup>TM</sup>-100 extruder apparatus (Aventin Inc., Ottawa, Canada) through polycarbonate filters 1.2 µm, 0.2 µm, 0.1 µm and 0.05 µm in size (Poetics Corp., Livermore CA, USA) to form liposomes in the size of 80-110 nm. The liposome solution was then passed through a 0.2 µm cellulose acetate sterilizing filter (Sterivex<sup>TM</sup>, Millipore Corporation, Bedford MA, USA) and stored at 2-8 °C.

10

**Real time interactions** – Surface Plasmon Resonance analysis. Binding studies were performed using a Biacore<sup>TM</sup> 2000 biosensor instrument (Biacore AB, Uppsala, Sweden). The following proteins were immobilized onto a CM5-sensor chip (Biacore AB, Uppsala, Sweden) at 1500RU(~1.5ng/mm<sup>2</sup>), by the amine coupling kit as prescribed by the supplier: FVIII (Kogenate-FS, Bayer, Berkley CA, USA), FIX (Benefix, Genetics Institute, Cambridge MA, USA), G-CSF, GM-CSF, IFN-γ, Erythropoietin, Human Growth Hormone, Interferon-alpha 2a, Interferon-alpha 2b (ProSpec-Tany TechnoGene Ltd, Nes Ziona, Israel), GLP-1, Insulin (Sigma), Copaxone (Teva Pharm, Israel), IgG and HSA (Omrix, Tel-Aviv, Israel). 15 SPR analysis was assessed in 50mM Na-citrate buffer (pH 7.0) at 25°C with a flow rate of 10µl/min for 4min using either PEGylated-liposomes or control-liposomes in a final concentration of 0.2-2 mM. Regeneration of the sensor chip surface was performed by washing the chip with 1mM NaOH for 1min at a flow rate of 10µl/min. Analysis of SPR data for association, dissociation and affinity constants 20 was carried out by BIA evaluation software (Biacore AB, Uppsala, Sweden).

**Multiple Alignments** - Multiple sequence alignment was carried out using MUSCA software (<http://cbcdrv.watson.ibm.com>). The following Swiss-Prot data base accession numbers were used for the multiple alignments: Human (h) FVIII

- 11 -

(P00451), hFIX (P00740), hG-CSF (P09919), hGM-CSF (P04141), hIFN- $\gamma$  (P01579), and hGLP-1 (P01275).

### 1.2 Results:

#### 5 Binding of proteins/peptides to PEGylated liposomes

We analyzed the binding of proteins and peptides to PEGylated liposomes by Surface Plasmon Resonance (SPR) measurement using a Biacore instrument (Biacore, Uppsala, Sweden). We immobilized proteins/peptides on a CM5 sensor chip (Biacore, Uppsala, Sweden), then injected PEGylated liposomes or control 10 liposomes of the same size (80-110 nm) and concentration and measured and analyzed the binding of protein/peptide to the flowed intake liposomes.

PEGylated liposomes composed of POPC and DSPE-PEG2000 bind to FVIII (Fig. 1a). The binding was dependant on the PEG polymer attached to DSPE lipid since two types of control liposomes composed of POPC and POPC:DSPE did 15 not bind to FVIII (Fig. 1a). In addition, the binding was specific to FVIII, since the PEGylated liposomes did not bind to human serum albumin (HSA) (Fig. 1b). Binding analysis of a representative curve (Fig. 1a) using a two-site binding model indicates that the PEGylated liposomes bind to two sites on FVIII with association rate constants ( $K_{on}$ ) of  $3.83 \times 10^5$  and  $3.37 \times 10^6$  M<sup>-1</sup> s<sup>-1</sup>, dissociation rate constants 20 ( $K_{off}$ ) of  $1.72 \times 10^{-3}$  and  $6.6 \times 10^{-3}$  s<sup>-1</sup> and affinity constant ( $K_d$ ) values of 1.96 nM and 4.5 nM respectively (Table 1).

Polyclonal anti human factor VIII antibodies [serum of a patient that developed anti FVIII antibodies (inhibitors)] compete with the binding of the PEGylated liposomes to both sites (Fig. 1c). Control experiment indicates that total 25 human immunoglobulin G (IgG) did not compete with the binding of FVIII to PEGylated liposomes (data not shown). This indicates that the PEGylated liposomes specifically bind to the same protein domains as anti human factor VIII antibodies.

SPR measurements were performed with several additional recombinant and 30 purified proteins. The following proteins were found bind to PEGylated liposomes:

- 12 -

Factor IX (FIX), Granulocyte colony-stimulating factor (G-CSF), Granulocyte macrophage colony-stimulating factor (GM-CSF), Interferon  $\gamma$  and Glucagon-Like Peptide 1 (GLP-1) (Fig 2-6). In addition, we found that the following proteins do not bind to the PEGylated liposomes: HSA, IgG, Insulin, Interferon  $\alpha$  2a,  
5 Interferon  $\alpha$  2b, Human growth hormone and Erythropoietin.

In addition, polyclonal anti human factor IX antibodies (Sigma) compete with the binding of the PEGylated liposomes to both sites (Fig. 7). This indicates that the PEGylated liposomes specifically bind to the same protein domains as anti human factor IX antibodies.

10 Amino acid sequence analysis indicate that there is a consensus sequence of 8 amino acids (S/T-X-L/I/V-I/V/Q/S-S/T-X-X-E) located within the proteins that binds the PEGylated liposomes (Fig. 8a) but is absent in proteins that do not bind the PEGylated liposomes. To test the consensus sequence and the identified binding sites on FVIII, we synthesized a peptide derived from amino acids 1783-1796 of  
15 FVIII and measured its binding to PEGylated liposomes. The peptide binds to PEGylated liposomes, but not to control POPC liposomes, with a  $K_d$  of 2.25 nM (Fig. 8c) which is similar to the  $K_d$  values of FVIII and PEGylated liposomes that were previously found (Table 1).

20 A summary of  $K_{on}$ ,  $K_{off}$  and  $K_d$  values of the various proteins and peptide is shown in Table 1.

However, Copaxone (Teva, Israel), a synthetic random copolymer composed of repeats of 4 amino acids (L-ala, L-glu, L-lys and L-tyr) but does not contain the consensus sequence, also binds PEGylated liposomes (Fig. 9)

- 13 -

**Table 1:** Kinetic parameter for the binding of proteins/peptide to PEGylated liposomes.

Protein/peptide	$k_{on}$ ( $s^{-1}$ )	$k_{off}$ ( $M^{-1}s^{-1}$ )	$K_d$ (M)
Factor VIII (1)	3.83x10 <sup>5</sup> ,	1.72x10 <sup>-3</sup> ,	1.96*10 <sup>-9</sup> ,
	3.37x10 <sup>6</sup>	6.6x10 <sup>-3</sup>	4.5*10 <sup>-9</sup>
Factor IX	3.33*10 <sup>6</sup>	0.021	6.3*10 <sup>-9</sup>
G-CSF	4.04*10 <sup>5</sup>	0.0137	3.39*10 <sup>-8</sup>
GM-CSF	8.5*10 <sup>5</sup>	0.0103	1.21*10 <sup>-8</sup>
INF- $\gamma$	1.44*10 <sup>6</sup>	4.16*10 <sup>-3</sup>	2.88*10 <sup>-9</sup>
GLP-1	1.16*10 <sup>5</sup>	2.21*10 <sup>-4</sup>	1.91*10 <sup>-9</sup>

5 Association and dissociation of various proteins and a peptide to PEGliposomes were assessed, as described in "material and methods". The PEGliposome concentrations tested were 18.355nM for FVIII, FIX, G-CSF, GM-CSF, INF- $\gamma$  and 183.55pM for GLP-1. The data obtained for all the proteins were analyzed to calculate association rate constants ( $k_{on}$ ), dissociation rate constants  
10 ( $k_{off}$ ) and affinity constants ( $K_d$ ) by BIAevaluation software.

## 2. Examples 9-10

### 2.1 Material & Methods

Formulation of FIX and G-CSF with PEGylated liposomes. PEGylated  
15 liposomes were formulated with either FIX (Octanine, Octapharma) or G-CSF (ProSpec-Tany TechnoGene Ltd, Nes Ziona, Israel) by dissolving the protein with liposome solution (one ml liposome solution/200 units of FIX and 1ml of liposome solution/10 $\mu$ g of G-CSF). The vial was incubated on a SRT1 roller mixer rotate at 33 rpm, amplitude 16 mm (Stuart Scientific, Redhill, UK) for 10 minutes (G-CSF)  
20 or 60 minutes (FIX), at room temperature (20-25°C).

Pharmacokinetics of liposome-formulated G-CSF and free G-CSF in mice. Two groups of C57 black mice were subcutaneously (s.c.) injected with: a) 50 $\mu$ l of

- 14 -

G-CSF formulated with PEGylated liposomes (10 $\mu$ g/ml). b) 50 $\mu$ l of G-CSF dissolved in 50mM Na-citrate buffer (10 $\mu$ g/ml). Mice were bled from retro-orbital sinus into microcentrifuge tubes containing sodium citrate (20 mM final concentration) at various times post injection and plasma was separated by 5 centrifugation at 2,700 x g for 10 minutes at 4 °C. G-CSF concentrations in mouse plasma was measured by ELISA (G-CSF DouSet ELISA kit, R&D) according to manufacturer instruction

Pharmacokinetics of PegLip-FIX and free FIX in hemophilic mice. Three groups of C57BL mice were injected IV into the tail vein with 50  $\mu$ l of: a) 200 units/ml PegLip-FIX. b) un-formulated FIX. c) buffer. Mice were bled from retro-orbital sinus into microcentrifuge tubes containing sodium citrate (20 mM final concentration) at various times post injection and plasma was separated by centrifugation at 2,700 x g for 10 minutes at 4 °C. FIX activity in mouse plasma was measured by one-stage clotting assay (using Stago reagents and ST4 clotting 10 machine) according to manufacturer's instruction. Since C57BL mice have endogenous FIX activity in their plasma, this endogenous activity (as measured in the control mice) was subtracted from the activity measured at each time-point in 15 the treated groups.

20            **Pharmacokinetics analysis**

Pharmacokinetic parameters (half life and AUC) were analyzed by computer software (RSTRIP, MicroMath Inc.).

25            **Statistic analysis**

**Student's t-test.**

**2.2 Results**

**Pharmacokinetics of liposome-formulated proteins in mice**

30            Pharmacokinetic parameters of free and liposome formulated FIX and G-CSF were measured in mice. The results presented in Tables 2-3 indicate that the

- 15 -

half-life and area under the curve of the proteins formulated with PEGylated liposomes were higher than that of free proteins.

5      **Table 2: Pharmacokinetic parameters following SC injection of liposome-formulated G-CSF (PegLip-G-CSF or free G-CSF into mice**

	T=1.75hr	T=3.75hr	T=5.75hr	T=7.75hr	T=9.33hr	HL (hr.)	AUC (pg*h/ml)
PegLip-G-CSF	58150.72 ±6299.95	56023.32 ±7372.35	48901.71 ±8991.09	24318.43 ±6512.68	14006.75 ±4278.52	5.038 0.896	434386.17 ±55926.46
G-CSF	T=2hr 62419.23 ±5212.47	T=4hr 50556.82 ±6928.12	T=6hr 37141.44 ±6068.82	T=8hr 12705.32 ±2780.72	T=9.58hr 5735.84 ±284.49	3.181 ±0.354	420746.83 ±40361.42

10      G-CSF was reconstituted with 50mM Na-citrate buffer pH 7 or formulated with PEGylated liposomes and injected (50 µl) s.c. into mice (6 mice in a group). Human G-CSF concentration (pg/ml) in the plasma was measured by an Enzyme Linked Immunosorbent Assay (Elisa). Pharmacokinetic parameters were calculated for each mouse. Values are means ± standard deviation. Student t-test analysis for half-life of PegLip-G-CSF *versus* G-CSF,  $P<0.002$ .

15      **Table 3: Pharmacokinetic parameters following IV injection of Factor IX or PEGylated liposome-formulated Factor IX (PegLip-FIX) into mice.**

	T=10min	T=4.83 hr	T=19.83hr	HL (hr.)	AUC (pg*h/ml)
PegLip-FIX	3.78±0.51	0.77±0.41	0.092±0.1	11.72	2.02
	T=10min	T=5hr	T=29hr		
FIX	3.85±0.39	0.63±0.31	0.081±0.078	10.96	1.85

20      Pharmacokinetic parameters were calculated for each mouse. Values are means ± standard deviation. Student t-test analysis for half-life of PegLip-FIX *versus* FIX,  $P<0.15$ .

- 16 -

### 3. Example 11

#### 3.1 Pharmacokinetics and biological activity of FVIII formulated *in-vivo* with PEGylated liposomes in hemophilic mice

5        Pharmacokinetics and biological activity of factor VIII, that was formulated *in-vivo* with PEGylated liposomes by injection of liposomes 1 hour after the injection of unformulated factor VIII, was measured in hemophilic mice. Hemophilic mice were injected with: a) free (unformulated) FVIII. b) Free FVIII and one hour later a second injection of PEGylated liposomes. The mice were bled  
10      at various times post-injection FVIII activity was measured by a clotting assay. In order to test *in-vivo* efficacy of liposome-formulated FVIII in stopping bleeding and compare it to that of free FVIII tails of the injected mice were cut several times post injection and the survival of the injected mice was measured.

The results presented in Table 4 and Figure 10 indicate that the half-life and  
15      area under the curve of factor VIII that was formulated *in-vivo* with PEGylated liposomes were higher than that of free FVIII. Accordingly, the survival of mice injected with FVIII and 1 hour later with liposomes were significantly higher.

- 17 -

**Table 4: Factor VIII activity (IU/ml) and pharmacokinetic parameters following injection of FVIII or FVIII and 1 hour later PEGylated liposomes into hemophilic mice**

5


Injection material	Time Post injection	T=10min	T=4.6h	T=8.3h	T=24.6 h	T=28.8 h	Half Life	Area under the curve
FVIII and liposomes (Injected 1 hour later)	Average (u/ml)	2.03	1.35	0.975	0.66	0.61	14.5	28.8
FVIII	Average (u/ml)	2.17	1.4	0.95	0.46	0.41	9.3	24.0

Recombinant FVIII (Kogenate-FS, Bayer) was reconstituted with water and injected (40 µl) into the tail vein of hemophilic mice (10 mice in each group). One hour later, PEGylated liposomes (9% lipids, w/v) were injected i.v. (40 µl) into one group of mice. FVIII activity was measured on pool plasma sample of each time-point by a one-stage clotting assay. Pharmacokinetic parameters (half life and AUC) were analyzed by a computer program (RSTRIP, MicroMath Inc.).

#### 4. Example 12

The binding of FVIII to liposomes composed of POPC and carbamate-linked uncharged lipopolymer was compared to the binding of FVIII to liposomes composed of POPC and DSPE-PEG by real time interaction analysis. The schematic structure of carbamate-linked uncharged lipopolymer: mPEG aminopropanediol distearoyl (DS-c-PEG) and 1,2 distearoyl-*sn*-glycero-3-phosphatidylethanolamine-N-methoxy polyethylene glycol (DSPE-PEG) are shown below.

— 18 —



15      The results are presented in Fig. 11 and show that both types of liposomes interacts with FVIII.

### 5. Example 13

Coagulation factor VIIa is generally used to treat hemophilia patients with inhibitors and to stop trauma bleeding (e.g. war injuries, car accidents). Pharmacokinetics of factor VIIa, formulated with PEGylated liposomes, was measured in rats. Sprague Dawley (SD) rats (180 g) rats were injected with 36 $\mu$ g/rat of free (unformulated) FVIIa (Nova Nordisk) or FVIIa formulated with PEGylated liposomes. The rats were bled at various times post-injection and FVIIa activity was measured by a clotting assay (Stago). The results presented in Tables 5 and 6 indicate that the half-life and area under the curve of factor VIIa that was formulated in-vivo with PEGylated liposomes were higher than that of free FVIIa.

- 19 -

Table 5: Factor VIIa activity (IU/ml) and pharmacokinetics following injection of FVIIa or rFVIIa formulated with pegylated liposomes into rats

Injected material	Time post-injection	T=10min	T=3 hrs	T=7 hrs	T=24 hrs	T=30 hrs	Half Life (HL) (h)	Area under the curve (AUC)
PEGLi-p-rFVIIa (n=4)	Average (U/ml) ± SD	573 ± 255	38 ± 8	7 ± 1	1.6 ± 1	0.5 ± 0.2	3.08	2013
rFVIIa (n=4)	Average (U/ml) ± SD	706 ± 45	45 ± 3	4.6 ± 1	0.1 ± 0.1	0	1.86	1411

Table 6: Factor VIIa activity (IU/ml) and pharmacokinetics following injection of FVIIa or rFVIIa formulated with pegylated liposomes into rats (pooled samples)

Injected material	T~10min	T~3 hrs	T~7 hrs	T~23 hrs	T~31 hrs	Half Life (HL) (h)	Area under the curve (AUC)
PEGLip-rFVIIa (n=3)	287	22.6	8.7	1.6	1.2	3.84	1019
rFVIIa (n=3)	319	27	5	0	0	1.15	513

- 20 -

**CLAIMS:**

1. A pharmaceutical composition for parenteral administration comprising a therapeutically effective amount of a protein or polypeptide and colloidal particles, said particles comprising approximately 1-20 mole percent of an 5 amphipathic lipid derivatized with a biocompatible hydrophilic polymer, wherein said protein or polypeptide is selected from the group consisting of:
  - (a) proteins or polypeptides capable of externally binding said colloidal particles;
  - (b) proteins or polypeptides capable of binding polymers of the polyalkylether, polylactic and polyglycolic acid families; and
  - (c) proteins or polypeptides that include a consensus sequence of S/T-X-L/I/V-I/V/Q/S-S/T-X-X-E, where X may be any amino acid, and S, T, L, I, V, E and Q have their standard meanings;wherein said protein or polypeptide is not Factor VIII (FVIII), and wherein said protein or polypeptide is not encapsulated in said colloidal 15 particles.
2. The pharmaceutical composition of Claim 1 wherein the colloidal particles are substantially neutral and the polymer carries substantially no net charge.
3. The pharmaceutical composition of Claim 1 wherein the colloidal particle 20 has a mean particle diameter of between about 0.03 to about 0.4 microns.
4. The pharmaceutical composition of Claim 3 wherein the colloidal particle has a mean particle diameter of approximately 0.1 microns.
5. The pharmaceutical composition of any of Claims 1-4 wherein said 25 amphipathic lipid is a phospholipid from natural or synthetic sources.
6. The pharmaceutical composition of Claim 5 wherein said amphipathic lipid is phosphatidylethanolamine (PE).
7. The pharmaceutical composition of any of Claims 1-4 wherein said amphipathic lipid is a carbamate-linked uncharged lipopolymer.

- 21 -

8. The pharmaceutical composition of Claim 7 wherein said amphipathic lipid is aminopropanediol distearoyl (DS)
9. The pharmaceutical composition of Claim 1 wherein said colloidal particles further comprise a second amphipathic lipid obtained from either natural or  
5 synthetic sources.
10. The pharmaceutical composition of Claim 9 wherein said second amphipathic lipid is phosphatidylcholine.
11. The pharmaceutical composition of Claim 9 wherein cholesterol is supplemented to the composition.
- 10 12. The pharmaceutical composition of Claim 1 wherein said biocompatible hydrophilic polymer is selected from the group consisting of polyalkylether, polylactic and polyglycolic acid families.
13. The pharmaceutical composition of Claim 12 wherein said biocompatible hydrophilic polymer is polyethylene glycol.
- 15 14. The pharmaceutical composition of Claim 13 wherein the polyethylene glycol has a molecular weight of between about 500 to about 5000 daltons.
15. The pharmaceutical composition of Claim 14 wherein the polyethylene glycol has a molecular weight of approximately 2000 daltons.
16. The pharmaceutical composition of Claim 1 wherein the protein or polypeptide  
20 is selected from the group consisting of prothrombin, Factor VIIa, Factor X, Factor V, Factor IX (FIX), granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), interferon  $\gamma$ , glucagon-like peptide 1 (GLP-1) and Copaxone.
17. The pharmaceutical composition of Claim 16 wherein the polypeptide is  
25 Copaxone and the composition is used for the treatment of a disease selected from multiple sclerosis, diabetic neuropathy, senile dementia, Alzheimer's disease, Parkinson's Disease, facial nerve (Bell's) palsy, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis, status epilepticus, non-arteritic optic neuropathy, and vitamin deficiency.

- 22 -

18. The pharmaceutical composition of Claim 16 wherein the polypeptide is Factor VIIa and the composition is used hemophilia patients with inhibitors and for the treatment of trauma bleeding.
19. The pharmaceutical composition of Claim 1 wherein the protein or polypeptide 5 comprises an amino acid consensus sequence of S/T-X-L/I/V-I/V/Q/S-S/T-X-X-E, wherein X is any amino acid.
20. Method of treatment of a patient suffering from hemophilia comprising administrating to said patient a pharmaceutical composition for parenteral administration comprising a therapeutically effective amount of a protein or 10 polypeptide effective in the treatment of hemophilia and colloidal particles, said particles comprising approximately 1-20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer,

wherein said protein or polypeptide is selected from the group consisting of:

  - (a) proteins or polypeptides capable of externally binding said colloidal 15 particles; and
  - (b) proteins or polypeptides capable of binding polymers of the polyalkylether, polylactic and polyglycolic acid families; and
  - (c) proteins or polypeptides that include a consensus sequence of S/T-X-L/I/V-I/V/Q/S-S/T-X-X-E, where X may be any amino acid, and S, T, 20 L, I, V, E and Q have their standard meanings;

wherein said protein or polypeptide is not Factor VIII (FVIII),  
and wherein said protein or polypeptide is not encapsulated in said colloidal particles.
21. A method according to Claim 20 wherein said patient has developed 25 inhibitor antibodies to said protein or polypeptide.
22. Use of a colloidal particle in the preparation of a pharmaceutical composition for parenteral administration for treatment of a patient suffering from hemophilia comprising a therapeutically effective amount of a protein or polypeptide and colloidal particles, said particles comprising

- 23 -

approximately 1-20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer,

wherein said protein or polypeptide is selected from the group consisting of:

- 5       (a) proteins or polypeptides capable of externally binding said colloidal particles; and
- (b) proteins or polypeptides capable of binding polymers of the polyalkylether, polylactic and polyglycolic acid families; and
- (c) proteins or polypeptides that include a consensus sequence of S/T-X-L/I/V-I/V/Q/S-S/T-X-X-E, where X may be any amino acid, and S, T, L, I, V, E and Q have their standard meanings;

wherein said protein or polypeptide is not Factor VIII (FVIII),

and wherein said said protein or polypeptide is not encapsulated in said colloidal particles.

15 23. A use according to Claim 22 wherein said patient has developed inhibitor antibodies to said protein or polypeptide.

24. Use of a colloidal particle in the preparation of a pharmaceutical composition for parenteral administration comprising a therapeutically effective amount of a protein or polypeptide and colloidal particles, said particles comprising approximately 1-20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer,

wherein said protein or polypeptide is selected from the group consisting of:

- 25       (a) proteins or polypeptides capable of externally binding said colloidal particles; and
- (b) proteins or polypeptides capable of binding polymers of the polyalkylether, polylactic and polyglycolic acid families; and
- (c) proteins or polypeptides that include a consensus sequence of S/T-X-L/I/V-I/V/Q/S-S/T-X-X-E, where X may be any amino acid, and S, T, L, I, V, E and Q have their standard meanings;

30       wherein said protein or polypeptide is not Factor VIII (FVIII),

- 24 -

and wherein said protein or polypeptide is not encapsulated in said colloidal particles.

25. Method of treatment of a patient suffering from a disease comprising administrating to said patient a pharmaceutical composition for parenteral administration comprising a therapeutically effective amount of a protein or polypeptide effective in the treatment of the disease and colloidal particles, said particles comprising approximately 1-20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer,

wherein said protein or polypeptide is selected from the group consisting of:

- 10 (a) proteins or polypeptides capable of externally binding said colloidal particles; and
- (b) proteins or polypeptides capable of binding polymers of the polyalkylether, polylactic and polyglycolic acid families; and
- (c) proteins or polypeptides that include a consensus sequence of S/T-X-L/I/V-I/V/Q/S-S/T-X-X-E, where X may be any amino acid, and S, T, L, I, V, E and Q have their standard meanings;

wherein said colloidal particles and said protein or polypeptide are administered separately,

and wherein said said protein or polypeptide is not encapsulated in said  
20 colloidal particles.

26. The method of claim 25 wherein said protein or polypeptide is not Factor VIII (FVIII).

27. The method of claim 25 wherein said colloidal particle is a liposome and said protein or polypeptide is Factor VIII (FVIII).

1/11





FIG. 1A

FIG. 1B

FIG. 1C



2/11




FIG. 2A




FIG. 2B

3/11




FIG. 3A




FIG. 3B

4/11




FIG. 4A




FIG. 4B

5/11




FIG. 5A




FIG. 5B

6/11




FIG. 6A




FIG. 6B

7/11






FIG. 7

8/11

**Consensus sequence S/T-X-L/I/V-I/V/Q/S-S/T-X-X-E**

FVIII	1787	SSLISYEE	1794
	1653	TTLQSDQE	1660
FIX	426	TGIIISWGE	433
G-CSF	188	SHLQSFL	195
GM-CSF	70	TCLQTRLE	77
Interferon- $\gamma$	70	SQIVS	74
GLP-1	105	SDVSSYLE	112

**FIG. 8A****FIG. 8B****FIG. 8C**

9/11




FIG. 9A




FIG. 9B

10/11




FIG. 10

11/11




FIG. 11

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/IL2004/000327

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61P7/02 A61P25/28

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, CHEM ABS Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 013 556 A (REDEMANN CARL T ET AL) 7 May 1991 (1991-05-07) *cf. col. 4, lines 34-51; col. 6, lines 10-30, col. 12, lines 7-21*	1-27
Y	WO 98/32466 A (FRANCIS GILLIAN ELIZABETH ; FISHER DEREK (GB); MALIK FAROOQ (GB); POLY) 30 July 1998 (1998-07-30) *cf. abstract, page 15, first para. bridging with page 16, line 20*	1-27
Y	WO 99/55306 A (BAR LILIANA ; BARU MOSHE (IL); NUR ISRAEL (IL); OPPERBAS HOLDING BV (N) 4 November 1999 (1999-11-04) *cf. abstract, page 6, line 24 bridging with page 7, line 12, claims 18/19*	1-27

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
14 July 2004	21/07/2004

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel: (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Stoltner, A

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/IL2004/000327

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 02/086117 A (BUTENAS, S., MANN, K.) 31 October 2002 (2002-10-31) *cf. page 5, 4th para. bridging with page 6, line 7, page 9, para. 5, page 11, para. 4, page 12, para. 3*	1-27

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/IL2004/000327

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5013556	A 07-05-1991	AT 115401 T AT 122229 T AU 642679 B2 AU 6637490 A AU 654120 B2 AU 6898291 A CA 2067133 A1 CA 2067178 A1 DE 69015207 D1 DE 69015207 T2 DE 69019366 D1 DE 69019366 T2 DK 496835 T3 EP 0496813 A1 EP 0496835 A1 ES 2071976 T3 FI 921763 A FI 921764 A GR 3017060 T3 HK 14097 A IL 96069 A IL 96070 A JP 2889549 B2 JP 10001431 A JP 5501264 T JP 2667051 B2 JP 5505173 T JP 2001181214 A KR 134982 B1 LU 88854 A9 NO 921213 A NO 921214 A US 5527528 A WO 9105545 A1 WO 9105546 A1 US 5620689 A US 5225212 A US 5213804 A US 2001051183 A1 US 5843473 A US 5356633 A	15-12-1994 15-05-1995 28-10-1993 16-05-1991 27-10-1994 16-05-1991 21-04-1991 21-04-1991 26-01-1995 04-05-1995 14-06-1995 05-10-1995 17-07-1995 05-08-1992 05-08-1992 01-07-1995 21-04-1992 30-11-1995 14-02-1997 08-12-1995 30-03-1995 10-05-1999 06-01-1998 11-03-1993 22-10-1997 05-08-1993 03-07-2001 22-04-1998 11-03-1997 04-06-1992 01-06-1992 18-06-1996 02-05-1991 02-05-1991 15-04-1997 06-07-1993 25-05-1993 13-12-2001 01-12-1998 18-10-1994
WO 9832466	A 30-07-1998	AT 200030 T AU 5773798 A DE 69800640 D1 DE 69800640 T2 EP 0921817 A1 WO 9832466 A1 JP 2001508783 T	15-04-2001 18-08-1998 03-05-2001 05-07-2001 16-06-1999 30-07-1998 03-07-2001
WO 9955306	A 04-11-1999	AU 747391 B2 AU 3441499 A BR 9909978 A CA 2329768 A1 EP 1079805 A1 WO 9955306 A1 JP 2002512947 T US 2003134778 A1	16-05-2002 16-11-1999 26-12-2000 04-11-1999 07-03-2001 04-11-1999 08-05-2002 17-07-2003

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No:  
PCT/IL2004/000327

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 9955306	A	US	6593294 B1	15-07-2003
WO 02086117	A	31-10-2002	WO 02086117 A1	31-10-2002